# US 2025/0145728 A1 · Preparation method and use of non-natural anti-human cd45ra murine chimeric antigen receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145728 A1
- Document ID: US20250145728A1
- Status: Published application
- Kind: A1
- Application number: 18/678,082
- Filed: 2024-05-30
- Published: 2025-05-08
- Earliest claimed: 2023-11-02
- Assignees: Zhejiang University; Children's Hospital of Zhejiang University School of Medicine
- Applicants: Zhejiang University; Children's Hospital of Zhejiang University School of Medicine
- Inventors: Yongmin TANG; Ping ZHANG; Yang TANG
- Web page: https://patentgrep.com/patent/US20250145728A1

## CPC

- C07K 16/289: {against CD45}
- A61P 35/02: specific for leukemia
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C12N 5/0636: {T lymphocytes}
- C12N 15/85: for animal cells
- C12N 15/86: Viral vectors
- C12N 15/867: Retroviral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides a preparation method of a non-natural anti-human CD45RA murine chimeric antigen receptor (CAR). In the present disclosure, eukaryotic expression vectors pcDNA3.1/Mu3A4-4-1BB-3ζ and pcDNA3.1/Mu3A4-4-1BB-3ζ-EGFP and a lentiviral expression vector pLenti/Mu3A4-4-1BB-3ζ are constructed based on molecular biology using a mouse-derived 3A4 antibody. The lentiviral expression vector pLenti/Mu3A4-4-1BB-3ζ can successfully infect human T cells and effectively kill 3A4-positive target cells such as KG1a cells and Raji cells. The recognition of antigens by Mu3A4CAR does not depend on antigen presentation process and is not restricted by a major histocompatibility complex (MHC), thus overcoming tumor immune evasion to kill 3A4-positive tumor cells more effectively.

## Claims

### Claim 1

A method for preparing a non-natural anti-human CD45RA murine chimeric antigen receptor (CAR), comprising: expressing a CAR protein through T cells and specifically binding the CAR protein to a human CD45RA antigen; wherein a target recognition domain (TRD) of the CAR is a human CD45RA antigen target; a MuCD45RACAR gene or a Mu3A4CAR gene comprises the following components: a CD8a leader serves as a leader sequence of the CAR, a murine CD45RA single-chain fragment variable (scFv) 3A4scFv serves as the TRD, a CD8a hinge serves as a hinge region, a CD8a transmembrane serves as a CAR transmembrane domain (TMD), and an intracellular signal transduction region of 4-1BB and an intracellular signal transduction region of CD3(are connected in series to form a complete murine CD45RACAR gene, namely the MuCD45RACAR gene or the Mu3A4CAR gene; a murine 3A4scFv heavy-chain gene has a nucleotide sequence shown in SEQ ID NO: 3 and an amino acid sequence shown in SEQ ID NO: 4, and a murine 3A4scFv light-chain gene has a nucleotide sequence shown in SEQ ID NO: 5 and an amino acid sequence shown in SEQ ID NO: 6.

### Claim 2 (depends on 1)

The method according to claim 1, specifically comprising the following steps:
(1) querying and comparing literatures to determine a basic structure of a second-generation 3A4CAR, retrieving the National Center for Biotechnology Information (NCBI) to verify gene sequences of a hinge region, a TMD, and an intracellular signal transduction region of the second-generation 3A4CAR, and synthesizing pUC/4-1BB-3ζ and pUC/4-1BB-3ζ-EGFP;
(2) constructing eukaryotic expression vectors pcDNA3.1/Mu3A4-4-1BB-3ζ and pcDNA3.1/Mu3A4-4-1BB-3ζ-EGFP and a lentiviral expression vector pLenti/Mu3A4-4-1BB-3ζ of the Mu3A4CAR gene; and
(3) conducting activity identification of the eukaryotic expression vectors and the lentiviral expression vector of the Mu3A4CAR gene: detecting whether the eukaryotic expression vectors and the lentiviral expression vector are expressed and whether protein localization is correct, comparing transfection and expression efficiencies of the eukaryotic expression vectors and the lentiviral expression vector, and selecting an optimal CAR expression vector.

### Claim 3

An effector cell, wherein the effector cell is a human T cell transfected through two expression vectors, namely a MuCD45RACAR-T cell or a Mu3A4CAR-T cell, wherein the two expression vectors comprises CD8a leader-CD45RAscFv-CD8a hinge-CD8a TMD-CD137-CD3ζ or CD8a leader-3A4scFv-CD8a hinge-CD8a TMD-CD137-CD3ζ, wherein the two expression vectors are an eukaryotic expression vector pcDNA3.1(+)-MuCD45RACAR or a pcDNA3.1(+)-Mu3A4CAR gene and a lentiviral expression vector pLenti-MuCD45RACAR or a pLenti-Mu3A4CAR gene, respectively.

### Claim 4 (depends on 1)

A method for treating a disease mediated by cells expressing CD45RA, comprising administering the non-natural anti-human CD45RA murine CAR prepared by the method according to claim 1 to a subject in need thereof, wherein the disease refers to a tumor disease expressing a CD45RA membrane antigen, mainly a malignant hematological disease, specifically comprising acute myeloid leukemia, acute lymphoblastic leukemia, and malignant lymphoma; and the diseases further comprises chronic myeloid leukemia and chronic lymphoblastic leukemia.
